Education
About Us
Working with TipRanks
Follow Us
JOINN Laboratories (China) Co., Ltd. Class H (HK:6127)
:6127
6127 Stock Chart & Stats
HK$21.12
HK$0.01(0.12%)
At close: 4:00 PM EST
HK$21.12
HK$0.01(0.12%)
Day’s Range― - ―
52-Week RangeHK$9.36 - HK$28.70
Previous CloseN/A
Volume546.17K
Average Volume (3M)6.46M
Market Cap
HK$28.32B
Enterprise ValueHK$26.15B
Total Cash (Recent Filing)HK$2.48B
Total Debt (Recent Filing)HK$31.53M
Price to Earnings (P/E)67.4
Beta1.44
Next Earnings
Mar 31, 2026EPS Estimate
0.34Next Dividend Ex-DateN/A
Dividend Yield0.15%
Share Statistics
EPS (TTM)0.03
Shares Outstanding118,995,210
10 Day Avg. Volume2,397,586
30 Day Avg. Volume6,458,364
Financial Highlights & Ratios
PEG Ratio-1.09
Price to Book (P/B)0.81
Price to Sales (P/S)3.26
P/FCF Ratio94.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Extremely Low LeverageExceptionally low leverage gives durable financial flexibility: the company can fund capex, R&D, dividends or opportunistic M&A without relying on external financing. This structural strength reduces solvency risk and supports resilience through multi-quarter industry slowdowns.
Strong Cash GenerationConsistent operating cash flow and a rebound in free cash flow provide a durable buffer for operations and shareholder distributions. Reliable cash generation supports reinvestment, dividend coverage and strategic flexibility even if revenue growth remains muted.
High Dividend SupportA materially high dividend yield, backed by positive free cash flow and minimal debt, creates a structural income proposition for investors. If cash generation persists, the dividend can anchor shareholder returns and constrain downside over multi-quarter horizons.
Bears Say
Revenue DeclineSustained revenue decline erodes scale and weakens the business model's growth engine. Over several quarters this reduces pricing leverage, limits reinvestment capacity, and makes recovery harder; persistent top-line weakness threatens long-term margin and earnings recovery.
Sharp Gross Margin CompressionA pronounced fall in gross margins indicates structural pressure from pricing, cost inflation, or adverse mix. Lower gross margins materially reduce operating leverage and sustainable profitability, making earnings and cash flow vulnerable unless the company restores pricing or cuts structural costs.
Low Return On EquityVery low ROE signals the business is generating weak returns on invested capital, limiting long-term shareholder value creation. Persistently low returns reduce reinvestment efficiency and make organic growth or value-accretive M&A necessary to improve structural profitability.
JOINN Laboratories (China) Co., Ltd. Class H News
6127 FAQ
What was JOINN Laboratories (China) Co., Ltd. Class H’s price range in the past 12 months?
JOINN Laboratories (China) Co., Ltd. Class H lowest stock price was HK$9.36 and its highest was HK$28.70 in the past 12 months.
What is JOINN Laboratories (China) Co., Ltd. Class H’s market cap?
JOINN Laboratories (China) Co., Ltd. Class H’s market cap is HK$28.32B.
When is JOINN Laboratories (China) Co., Ltd. Class H’s upcoming earnings report date?
JOINN Laboratories (China) Co., Ltd. Class H’s upcoming earnings report date is Mar 31, 2026 which is in 35 days.
How were JOINN Laboratories (China) Co., Ltd. Class H’s earnings last quarter?
JOINN Laboratories (China) Co., Ltd. Class H released its earnings results on Oct 31, 2025. The company reported HK$0.033 earnings per share for the quarter, missing the consensus estimate of HK$0.12 by -HK$0.087.
Is JOINN Laboratories (China) Co., Ltd. Class H overvalued?
According to Wall Street analysts JOINN Laboratories (China) Co., Ltd. Class H’s price is currently Overvalued.
Does JOINN Laboratories (China) Co., Ltd. Class H pay dividends?
JOINN Laboratories (China) Co., Ltd. Class H pays a Annually dividend of HK$0.033 which represents an annual dividend yield of 0.15%. See more information on JOINN Laboratories (China) Co., Ltd. Class H dividends here
What is JOINN Laboratories (China) Co., Ltd. Class H’s EPS estimate?
JOINN Laboratories (China) Co., Ltd. Class H’s EPS estimate is 0.34.
How many shares outstanding does JOINN Laboratories (China) Co., Ltd. Class H have?
JOINN Laboratories (China) Co., Ltd. Class H has 118,995,210 shares outstanding.
What happened to JOINN Laboratories (China) Co., Ltd. Class H’s price movement after its last earnings report?
JOINN Laboratories (China) Co., Ltd. Class H reported an EPS of HK$0.033 in its last earnings report, missing expectations of HK$0.12. Following the earnings report the stock price went up 3.276%.
Which hedge fund is a major shareholder of JOINN Laboratories (China) Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6127
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
JOINN Laboratories (China) Co., Ltd. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
122.02%
12-Months-Change
Fundamentals
Return on Equity
2.74%
Trailing 12-Months
Asset Growth
-0.03%
Trailing 12-Months
Company Description
JOINN Laboratories (China) Co., Ltd. Class H
Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics studies, and pharmacology and efficacy studies. The Clinical Trial and Related Services segment provides clinical CRO services, co-managed phase I clinical research units, and bioanalytical services. The Sales of Research Models segment designs, produces, breeds, and sells research models, non-human primates, and rodents. The company also offers investment management and cell-based assay (CBA) services. Joinn Laboratories(China)Co.,Ltd. was founded in 1995 and is headquartered in Beijing, China.
Technical Analysis
Hangzhou Tigermed Consulting Co., Ltd. Class H
―
Shanghai Conant Optical Co. Ltd. Class H
―
WuXi AppTec Co., Ltd. Class H
―
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
―
Options Prices
Currently, No data available
---